SCD1 inhibitor-3
Based on 1 Customer Validation
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.
For research use only. We do not sell to patients.
- Purity : 98.24%
- CAS No.: 1282606-48-7
- Formula: C19H16FN7O2
- Molecular Weight:393.37
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-13070
MK-8245 -
HY-50709
A939572SCD1 Inhibitor -
HY-15823
CAY10566SCD1 Inhibitor -
HY-19796
Icomidocholic acidSCD1 Inhibitor -
HY-124751
YTX-465Ole1/SCD Inhibitor -
HY-15822
MF-438SCD1 Inhibitor -
HY-141525
SCD1 inhibitor-4SCD1 Inhibitor -
HY-112812
SCD1 inhibitor-1SCD1 inhibitor -
HY-100249
XEN723SCD1 Inhibitor -
HY-N6807
ElemicinSCD Inhibitor -
HY-19762
GSK1940029Stearoyl-coa Desaturase Inhibitor -
HY-11034
CVT-12012SCD Inhibitor
Biological Activity
Description
IC50 & Target
SCD1[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
103 nM
Compound: 17a
|
Inhibition of SCD1 in human HepG2 cells using [14C]-stearate substrate assessed as decreased production of [14C]-oleic acid after 24 hrs
Inhibition of SCD1 in human HepG2 cells using [14C]-stearate substrate assessed as decreased production of [14C]-oleic acid after 24 hrs
|
[PMID: 25555732] |
In Vivo
SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lewis rats[1]
-
Dosage:5 mg/kg
-
Administration:P.o.; 4 hours
-
Result:Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.
-
Animal Model:Lewis rats[1]
-
Dosage:2~10 mg/kg
-
Administration:P.o.; 4 hours
-
Result:A dose-responsive reduction of plasma triglycerides desaturation index.
Chemical Information
-
CAS No. 1282606-48-7
-
Appearance Solid
-
Molecular Weight 393.37
-
Formula C19H16FN7O2
-
Color White to off-white
-
SMILES
O=C(C1=NNC(N2C=NN(CC3=CC=C(F)C=C3)C2=O)=C1)NCC4=CC=CN=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : ≥ 125 mg/mL (317.77 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5421 mL | 12.7107 mL | 25.4214 mL | 63.5534 mL |
| 5 mM | 0.5084 mL | 2.5421 mL | 5.0843 mL | 12.7107 mL | |
| 10 mM | 0.2542 mL | 1.2711 mL | 2.5421 mL | 6.3553 mL | |
| 15 mM | 0.1695 mL | 0.8474 mL | 1.6948 mL | 4.2369 mL | |
| 20 mM | 0.1271 mL | 0.6355 mL | 1.2711 mL | 3.1777 mL | |
| 25 mM | 0.1017 mL | 0.5084 mL | 1.0169 mL | 2.5421 mL | |
| 30 mM | 0.0847 mL | 0.4237 mL | 0.8474 mL | 2.1184 mL | |
| 40 mM | 0.0636 mL | 0.3178 mL | 0.6355 mL | 1.5888 mL | |
| 50 mM | 0.0508 mL | 0.2542 mL | 0.5084 mL | 1.2711 mL | |
| 60 mM | 0.0424 mL | 0.2118 mL | 0.4237 mL | 1.0592 mL | |
| 80 mM | 0.0318 mL | 0.1589 mL | 0.3178 mL | 0.7944 mL | |
| 100 mM | 0.0254 mL | 0.1271 mL | 0.2542 mL | 0.6355 mL |
SCD1 inhibitor-3 Related Classifications
HY-139077 Related Classifications
Powered by Bioz